evofem biosciences inc said it has received a deficiency letter from the nasdaq stock market the letter notified the company that the closing bid price for its stock for the preceding 30 consecutive trading days was below the minimum 1 a share requirement for continued inclusion on the nasdaq capital market evofem biosciences said friday the company said it has an initial period of 180 calendar days or until feb 21 2022 to regain compliance with the bid price requirement it added that the notification has no immediate effect on its nasdaq listing evofem biosciences said it will get a written confirmation of compliance if its stock is at least 1 a share for a minimum of 10 consecutive business days it also could be eligible for an additional compliance period of 180 calendar days it said to qualify for that the company said it would need to meet nasdaqs requirement for market value of publicly held shares and other initial listing standards with the exception of the bid price requirement and would need to provide a written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split if needed